Phase I clinical trials are underway for the glutaminase inhibitor CB-839 (NCT02071927) and oxidative phosphorylation inhibitor IACS-010759 (NCT02882321) in patients with relapsed or refractory AML (82), as well as safety and tolerability of adding HMG-CoA inhibitor pitavastatin to venetoclax in subjects with newly diagnosed AML (NCT04512105). The gene discussed is GLS; the disease is acute myeloid leukemia.